Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)

What is the purpose of this trial?

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Participation Guidelines

Ages: 18 years and younger

Gender: Both

Esperion Therapeutics

Start Date: 10/17/2017

End Date: 12/31/2021

Last Updated: 02/22/2018

Study HIC#: 2000020628

Get Involved

For more information about this study, contact:
Nancy J. Hinchion
+1 203-453-7056

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Jaime Gerber

Principal Investigator